title: Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
abstract: OBJECTIVE
  To evaluate the effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
  
  
  METHODS
  A randomized, double-blind, placebo-controlled clinical trial was carried out in 12 obese, dyslipidaemic patients, independently of their basal insulin sensitivity. At the beginning of the study, a metabolic profile was measured, and insulin sensitivity estimated using the euglycaemic-hyperinsulinaemic clamp technique. The volunteers were randomly assigned to receive ezetimibe (10 mg/day in the morning) or placebo for a period of 90 days. After intervention, a similar metabolic profile was measured and a second clamp study was performed.
  
  
  RESULTS
  Ezetimibe administration for 90 days decreased total (6.0 +/- 0.5 vs. 4.2 +/- 0.9 mmol/L, p = 0.011) and low-density lipoprotein (4.0 +/- 0.7 vs. 2.2 +/- 0.8 mmol/L, p=0.003) cholesterol concentrations without modification of insulin sensitivity (3.0 +/- 0.6 vs. 2.9 +/- 0.7 mg/kg/min, p = 0.345).
  
  
  CONCLUSIONS
  Ezetimibe significantly decreased total cholesterol and low-density lipoprotein cholesterol concentrations without affecting insulin sensitivity in obese and dyslipidaemic patients.
authors.affiliation: Medical Research Unit in Clinical Epidemiology, Specialties Hospital, West National Medical Center, Mexican Institute of Social Security, Belisario Domínguez, Colonia Independencia, Guadalajara, Jalisco. uiec@prodigy.net.mx
authors.forename: Manuel
authors.initials: M
authors.lastname: González-Ortiz
authors.forename: Esperanza
authors.initials: E
authors.lastname: Martínez-Abundis
authors.forename: Angélica María
authors.initials: AM
authors.lastname: Kam-Ramos
authors.forename: Eduardo
authors.initials: E
authors.lastname: Hernández-Salazar
authors.forename: Maria Guadalupe
authors.initials: MG
authors.lastname: Ramos-Zavala
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001795:Blood Pressure Determination; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D001786:Blood Glucose; D008078:Cholesterol, LDL; D008055:Lipids; D002784:Cholesterol; D000069438:Ezetimibe